WO2022139458A1 - 피부 개선용 조성물 - Google Patents
피부 개선용 조성물 Download PDFInfo
- Publication number
- WO2022139458A1 WO2022139458A1 PCT/KR2021/019608 KR2021019608W WO2022139458A1 WO 2022139458 A1 WO2022139458 A1 WO 2022139458A1 KR 2021019608 W KR2021019608 W KR 2021019608W WO 2022139458 A1 WO2022139458 A1 WO 2022139458A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sitosterol
- beta
- skin
- composition
- linoleic acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 229940076810 beta sitosterol Drugs 0.000 claims abstract description 76
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims abstract description 76
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims abstract description 76
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims abstract description 76
- 229950005143 sitosterol Drugs 0.000 claims abstract description 76
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 67
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 67
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 67
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 claims abstract description 50
- 229940026455 cedrol Drugs 0.000 claims abstract description 49
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000002537 cosmetic Substances 0.000 claims abstract description 49
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 claims abstract description 49
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims abstract description 45
- 229940114124 ferulic acid Drugs 0.000 claims abstract description 45
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims abstract description 45
- 235000001785 ferulic acid Nutrition 0.000 claims abstract description 45
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims abstract description 45
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims abstract description 45
- 230000037303 wrinkles Effects 0.000 claims abstract description 29
- 238000009472 formulation Methods 0.000 claims abstract description 25
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 24
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 23
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 22
- 235000013305 food Nutrition 0.000 claims abstract description 22
- 108010035532 Collagen Proteins 0.000 claims abstract description 19
- 102000008186 Collagen Human genes 0.000 claims abstract description 19
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 19
- 229920001436 collagen Polymers 0.000 claims abstract description 19
- 230000037394 skin elasticity Effects 0.000 claims abstract description 18
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 17
- 230000002087 whitening effect Effects 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 230000001603 reducing effect Effects 0.000 claims abstract description 3
- 230000003020 moisturizing effect Effects 0.000 claims description 24
- 230000003078 antioxidant effect Effects 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 19
- 239000003963 antioxidant agent Substances 0.000 claims description 18
- 239000006210 lotion Substances 0.000 claims description 16
- -1 pack Substances 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 10
- 230000001737 promoting effect Effects 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 6
- 239000003599 detergent Substances 0.000 claims description 6
- 239000000686 essence Substances 0.000 claims description 6
- 230000007760 free radical scavenging Effects 0.000 claims description 6
- 239000000865 liniment Substances 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 241000021559 Dicerandra Species 0.000 claims 5
- 230000000694 effects Effects 0.000 abstract description 13
- 239000004480 active ingredient Substances 0.000 abstract description 10
- 230000009467 reduction Effects 0.000 abstract description 5
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 abstract description 3
- 230000003064 anti-oxidating effect Effects 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 description 58
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 230000000052 comparative effect Effects 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 15
- 235000006708 antioxidants Nutrition 0.000 description 14
- 239000002994 raw material Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 230000037319 collagen production Effects 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Definitions
- the present invention Cedrol (Cedrol); And beta-sitosterol (Beta-sitosterol) and linoleic acid (Linoleic acid) one or more selected from the group consisting of; or ferulic acid; And beta-sitosterol (Beta-sitosterol) and linoleic acid (Linoleic acid); for antioxidant; For improving skin elasticity or improving wrinkles; or for moisturizing the skin; It relates to cosmetic, food and quasi-drug compositions.
- Human skin color is determined by several factors such as melanocyte activity, blood vessel distribution, skin thickness, and the presence or absence of pigments inside and outside the human body.
- enzymes such as tyrosinase are The black pigment called melanin, which is produced by action, is important.
- Melanin exists in the skin and plays an important role in protecting the body from ultraviolet rays, etc., but when it is overproduced, it is known to promote pigmentation and skin aging, and to play a major role in inducing skin cancer.
- Collagen is a major matrix protein produced in fibroblasts of the skin, and functions such as maintaining the mechanical firmness of the skin and tissue bonding, supporting cell adhesion, and inducing cell differentiation. Collagen decreases due to age increase and photoaging by UV irradiation, and collagen reduction is promoted by the activity of collagenase enzyme that decomposes collagen. This is known to be closely related to the formation of wrinkles on the skin.
- hyaluronic acid present in the body of a mammal is distributed in the skin, particularly the intercellular space of the epidermis and the connective tissue of the dermis. It is known that the amount of hyaluronic acid in the skin decreases with aging, and the decrease in hyaluronic acid in the skin is considered to be one of the direct causes of the decrease in the moisture content of the skin. Therefore, skin moisturizing and hyaluronic acid are closely related.
- retinol, adenosine, chlorella extract, etc. are known as skin elasticity enhancement and wrinkle improvement cosmetics.
- Retinol promotes collagen synthesis and inhibits the elastase enzyme, but it is unstable and has limited usage due to safety issues such as irritation and rash when applied to the skin.
- cedrol Cedrol
- ferulic acid beta-sitosterol
- Beta-sitosterol Beta-sitosterol
- linoleic acid Lileic acid
- Cedrol than when the formulation was prepared alone
- ferulic acid beta-sitosterol
- linoleic acid Lileic acid
- the present invention for cosmetics, food or quasi-drugs, Cedrol (Cedrol); And beta-sitosterol (Beta-sitosterol) and linoleic acid (Linoleic acid) at least one selected from the group consisting of; provides a composition for improving skin comprising as an active ingredient.
- the present invention for cosmetics, food or quasi-drugs, ferulic acid (Ferulic acid); And beta-sitosterol (Beta-sitosterol) and linoleic acid (Linoleic acid) at least one selected from the group consisting of; provides a composition for improving skin comprising as an active ingredient.
- Cedrol Cedrol
- Beta-sitosterol beta-sitosterol
- one or more selected from the group consisting of linoleic acid (Linoleic acid) linoleic acid
- it provides a method of improving wrinkles, or moisturizing the skin.
- Cedrol Cedrol
- Beta-sitosterol beta-sitosterol
- one or more selected from the group consisting of linoleic acid Or it provides a method of improving wrinkles, or moisturizing the skin.
- ferulic acid Ferulic acid
- Beta-sitosterol Beta-sitosterol
- linoleic acid Linoleic acid
- ferulic acid Ferulic acid
- Beta-sitosterol Beta-sitosterol
- one or more selected from the group consisting of linoleic acid Or it provides a method of improving wrinkles, or moisturizing the skin.
- composition according to the present invention can improve skin by removing free radicals, reducing melanin, promoting collagen synthesis, and promoting hyaluronic acid synthesis. It can be effectively used in cosmetics, food or quasi-drugs for
- Cedrol Cedrol
- ferulic acid When the formulation was prepared alone, there is a problem that formulation stability is considerably low (Examples 7 and 11 of Experimental Example 2). But Cedrol; Or ferulic acid; beta-sitosterol (Beta-sitosterol) and linoleic acid (Linoleic acid); in combination with one or more selected from the group consisting of Examples 8 to 10, Examples 12 to 14, Cedrol; Or ferulic acid; it was confirmed that no precipitation. Thus, Cedrol; Alternatively, it was confirmed that formulation stability was increased when combined with beta-sitosterol and linoleic acid than when using ferulic acid alone.
- the present invention Cedrol (Cedrol);
- Beta-sitosterol (Beta-sitosterol) and linoleic acid; provides
- ferulic acid Ferulic acid
- Beta-sitosterol (Beta-sitosterol) and linoleic acid; provides
- Cedrol Cedrol
- Beta-sitosterol beta-sitosterol
- Cedrol Cedrol
- Beta-sitosterol beta-sitosterol
- one or more selected from the group consisting of linoleic acid Or it provides a method of improving wrinkles, or moisturizing the skin.
- a cosmetic for skin whitening, antioxidant, skin elasticity enhancement or wrinkle improvement, or skin moisturizing food; Or quasi-drugs; Cedrol for manufacturing; And beta-sitosterol (Beta-sitosterol) and linoleic acid (Linoleic acid), one or more selected from the group consisting of; provides the use of a composition comprising as an active ingredient.
- ferulic acid Ferulic acid
- Beta-sitosterol beta-sitosterol
- linoleic acid Linoleic acid
- ferulic acid Ferulic acid
- Beta-sitosterol Beta-sitosterol
- one or more selected from the group consisting of linoleic acid Or it provides a method of improving wrinkles, or moisturizing the skin.
- Skin whitening of the present invention not only brightens the skin tone by inhibiting the synthesis of melanin, but also inhibits or prevents melanin deposition (hyperpigmentation), and relieves spots and freckles caused by UV rays, hormones or heredity Or it means any action that improves.
- Antioxidant refers to inhibiting oxidation of cells by highly reactive free radicals or reactive oxygen species (ROS) depending on intracellular metabolism or oxidative stress caused by the influence of ultraviolet rays.
- ROS reactive oxygen species
- the free radical scavenging effect was confirmed through the DPPH reduction effect confirmed in the experiment.
- free radical refers to an atom or molecule having one binocular electron. Hydrogen atom, chlorine atom, etc. are monoatomic free groups. Usually, what is called a free radical is one in which one proton is released from an inorganic or organic compound molecule and there is one unpaired electron in the residue. Free radicals have excellent chemical reactivity, and free radicals induced by them affect various reactions in the body and cause aging. Organisms are always exposed to the harmful effects caused by free radicals, and as the cells age, the harmfulness gradually accumulates and causes various diseases. Therefore, free radical scavenging plays an important role in the antioxidant effect.
- the "enhancement of skin elasticity” of the present invention means to alleviate the degree of sagging or sagging of the skin.
- wrinkle improvement means preventing, suppressing or inhibiting the formation of wrinkles on the skin, or alleviating the wrinkles already formed. In the present invention, the effect of promoting collagen synthesis was confirmed, and the effect of enhancing skin elasticity and improving wrinkles was confirmed.
- “Moisturizing skin” of the present invention means to increase the feeling of moisture in the skin and to maintain a moist state by suppressing moisture loss.
- the skin moisturizing effect was confirmed by confirming the hyaluronic acid synthesis promoting effect.
- the "cosmetic composition” of the present invention may be in the form of a general emulsified formulation and a solubilized formulation.
- lotions such as flexible lotion or nourishing lotion, milky lotion such as facial lotion and body lotion, cream such as nourishing cream, moisture cream, eye cream, essence, cosmetic ointment, balm, spray, gel, pack, sunscreen , makeup base, liquid type, solid type or spray type foundation, powder, cleansing cream, cleansing lotion, makeup remover such as cleansing oil, cleansing agent such as cleansing foam, soap, body wash, and the like.
- the cosmetic includes a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, Ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any conventionally used in cosmetics It may contain adjuvants commonly used in the field of cosmetology such as other ingredients of
- the cosmetic formulation may include a relatively high concentration of the composition of the present invention in the case of wash-off type cosmetics such as makeup removers and detergents in which the active ingredient stays on the skin within a short period of time.
- wash-off type cosmetics such as makeup removers and detergents
- leave-on type cosmetics such as lotions, emulsions, creams, and essences
- the composition of the present invention at a lower concentration than the wash-off type cosmetics. would be free to include.
- the composition comprises 0.0001% to 10% by weight (preferably 0.0001% to 1% by weight) of the composition of the present invention based on the total weight of the composition.
- composition of the present invention contains less than 0.0001% by weight of the composition of the present invention, sufficient skin whitening; antioxidant; For improving skin elasticity or improving wrinkles; Alternatively, the skin moisturizing effect cannot be expected, and when it contains more than 10% by weight, an unwanted reaction such as an allergy may occur or there may be a problem in skin safety, so this is to prevent this.
- Food composition refers to a food composition prepared by adding the composition of the present invention to food materials such as beverages, teas, spices, gum, and confectionery, or encapsulating, powdering, suspension, or the like.
- the above food formulations can be consumed on a daily basis, so skin whitening; antioxidant; For improving skin elasticity or improving wrinkles; Alternatively, the skin moisturizing effect can be expected, which is very useful.
- the composition of the present invention When the composition of the present invention is used as a food additive, the composition of the present invention may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method.
- the mixed amount of the active ingredient may be suitably determined according to the purpose of its use (prevention, health or therapeutic treatment).
- the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material.
- the amount may be less than or equal to the above range.
- foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, There are alcoholic beverages, vitamin complexes, and the like, and includes all health foods in the ordinary sense.
- the food formulation When the food formulation is a beverage, it may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional beverage.
- the above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- natural sweeteners such as taumartin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like can be used.
- the proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.
- food formulations include various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonated beverages It may contain a carbonation agent, etc. used for Other food formulations may contain the pulp for the production of natural fruit juices, fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The proportion of these additives is not particularly important, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
- the "quasi-drug composition" of the present invention refers to an article that is used for the purpose of diagnosing, treating, alleviating, treating or preventing a human or animal disease, but has a milder effect on the human body than a drug, and is not an instrument, machine or device among articles It means a composition for articles other than instruments, machines, or devices among articles used for the purpose of pharmacologically affecting the structure and function of humans or animals. Except for articles used for pharmaceutical purposes according to the Pharmaceutical Affairs Act, one embodiment may include, but is not limited to, external preparations for skin, personal care products, or preparations for internal use. Components and the like may be appropriately selected from conventional techniques known in the art.
- the present invention Cedrol (Cedrol);
- Beta-sitosterol and one or more selected from the group consisting of linoleic acid (Linoleic acid); provides a pharmaceutical composition for skin whitening, antioxidant, skin elasticity enhancement or wrinkle improvement or skin moisturizing, including;
- ferulic acid Ferulic acid
- Beta-sitosterol and one or more selected from the group consisting of linoleic acid (Linoleic acid); provides a pharmaceutical composition for skin whitening, antioxidant, skin elasticity enhancement or wrinkle improvement or skin moisturizing, including;
- composition of the present invention can be administered orally or parenterally, and when the composition of the present invention is used as a pharmaceutical composition, it is in the form of a generic pharmaceutical preparation, for example, various oral and parenteral dosage forms during clinical administration In the case of formulation, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants, but is not limited thereto.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the pharmaceutical composition of the present invention, for example, starch, calcium carbonate, water Cross (Sucrose) or lactose (Lactose), it may be prepared by mixing gelatin, but is not limited thereto.
- excipient for example, starch, calcium carbonate, water Cross (Sucrose) or lactose (Lactose)
- lubricants such as magnesium stearate talc are also used.
- Liquid formulations for oral use include suspensions, solutions, emulsions, syrups, etc.
- various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. may be included. not limited
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
- Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
- injectable esters such as ethyl oleate.
- witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, etc. may be used, but is not limited thereto.
- composition of the present invention can be used for the preparation of cosmetic formulations.
- the cosmetic formulation is the same as described above in the description of the cosmetic formulation comprising the composition of the present invention.
- each of the above-mentioned components included in the composition according to the present invention may be included in the composition of the present invention, preferably within a range not exceeding the maximum amount specified in the norms stipulated by the respective national governments.
- a pharmaceutical composition it may be included in the present invention within the scope of the manufacturing method, properties, amount of use, etc. specified in the Pharmacopoeia or drug collection prescribed in Korea, the United States, Europe, Germany, Japan, China, etc. .
- a cosmetic composition it will be included in the cosmetic composition of the present invention to the extent that it does not exceed the maximum amount specified in the Cosmetic Safety Act stipulated by each country or the “Cosmetic Safety Technical Specification” stipulated by the Chinese government. can
- a sample was prepared by dissolving the component in methanol as described above.
- the concentration of each component of the sample was adjusted according to the experimental methods of Experimental Examples 1 to 4 below.
- Comparative Examples 1 to 4 and Examples 1 to 6 solutions were prepared using methanol as a solvent so that the concentration of each component in the solution was 0.5 mg/mL.
- the free radical scavenging ability was evaluated by 1,1-diphenyl-2-picrylhydrazyl (DPPH) method. measured.
- DPPH 1,1-diphenyl-2-picrylhydrazyl
- DPPH is a relatively stable free radical. When it exists in a radical state, it exhibits a maximum absorption at 517 nm, but loses its absorption ability when the radical is removed.
- DPPH was dissolved in methanol at a concentration of 0.12 mM and used.
- MNT-1 melanoma cells were aliquoted in a 6-well plate at a concentration of 1 to 2 x 10 5 cells/mL and cultured for 24 hours. Samples were treated so that the concentration of each component of Comparative Examples 1 to 4 and Examples 1 to 6 was finally 3 ⁇ g/mL (3 ppm), and then cultured for 72 hours.
- arbutin was treated to be 200 ⁇ g/mL (200 ppm) (positive control in Table 3).
- the cells were treated with trypsin, removed from the culture vessel, centrifuged at 13,000 rpm for 1 minute, and the supernatant was removed.
- the cells were lysed (Lysis) by adding 300 ⁇ L of 0.5% Triton X-100 solution to the remaining cells. This was again centrifuged at 13,000 rpm for 3 minutes to separately collect the precipitate (Pellet) and the supernatant.
- 100 ⁇ L of 0.5 N sodium hydroxide solution was added and dissolved by incubation for 12 hours, and the total amount of melanin produced was measured by measuring the absorbance at 450 nm using a spectrophotometer.
- a mixture of DMEM and 10% FBS was used as a basic medium for culturing human-derived fibroblasts.
- Skin fibroblasts were aliquoted in a 48-well plate at a concentration of 2-5 x 10 4 cells/mL and cultured for 24 hours.
- a positive control inducing collagen synthesis was treated with TGF- ⁇ to a concentration of 5 ng/mL (5 ppb) (positive control in Table 4).
- the cell culture medium was taken and the synthesized collagen was measured using the Human procollagen 1 ⁇ 1 duoset ELISA Kit (R&D Systems) and a spectrophotometer.
- a calibration curve was prepared by measuring the separated and purified collagen at concentrations of 0.25, 0.5, 1, 2, 4, and 8 ng/mL. Based on this, Comparative Examples 1 to 4 and Examples 1 to 6, negative control group, and positive control group's collagen (Type I collagen) production amount was calculated. The amount of collagen produced compared to the methanol-treated group (negative control group) was calculated as the collagen production rate (%) (Equation 2), and the experiment was performed three times, and the average value was calculated and shown in Table 4.
- Collagen production rate (%) (collagen production amount of the group treated with each Example - collagen production amount of the group treated with methanol) / (collagen production amount of the group treated with methanol) * 100 (Equation 2)
- Keratinocytes Primary cultured human skin keratinocytes were purchased from Thermo Fisher Scientific and cultured using Keratinocyte-SFM supplemented with Epidermal Growth Factor (EGF) and Bovine Pituitary Extract (BPE). Keratinocytes were aliquoted in a 60-mm culture plate at a concentration of 2-5 x 10 5 cells/mL and cultured for 24 hours. Remove the basal medium with the growth factor, and add a medium with a final concentration of 3 ⁇ g/mL (3 ppm) of each component of Comparative Examples 1 to 4 and Examples 1 to 6 (medium without EGF and BPE) Incubated for 24 hours.
- EGF Epidermal Growth Factor
- BPE Bovine Pituitary Extract
- a positive control inducing hyaluronic acid synthesis was treated with all-trans-Retinoic acid to 100 nM (positive control in Table 5).
- the cell culture medium was taken and synthesized hyaluronic acid was measured using a Hyaluronan DuoSet ELISA Kit (R&D Systems) and a spectrophotometer.
- a calibration curve was prepared by measuring standard hyaluronic acid at concentrations of 1.1, 3.3, 10, 30, and 90 ng/mL, and based on this, Comparative Examples 1 to 4 and Examples 1 to 6, negative control group, and hyaluronic acid production amount of Comparative Example 3 was calculated.
- the amount of hyaluronic acid produced compared to the methanol-treated group (negative control group) was calculated as the hyaluronic acid production rate (%) (Equation 3). After the experiment was performed three times, the average value was calculated and shown in Table 5.
- Hyaluronic acid production rate (%) (Hyaluronic acid production in the group treated with Example - Hyaluronic acid production in the group treated with methanol) / (Hyaluronic acid production in the group treated with methanol) * 100 (Equation 3)
- Example 7 the raw materials 3 and 4 were dispersed in the raw material 2 at the composition ratio (unit weight %) shown in Table 6 below, and then the raw material 5 was added and dissolved. After confirming the dissolution, the raw materials 6-8 were dissolved and stirred uniformly.
- Raw materials 9-11 were sequentially added to Raw Material 1 and uniformly stirred, and the ethanol phase was gradually added to the aqueous phase and stirred uniformly for 10 minutes to prepare a cosmetic solution.
- Examples 8-10 were prepared in the same manner as in Example 7.
- Example 7 Example 8
- Example 9 Example 10
- Beta-sitosterol - 0.1 - 0.1 4 Linoleic acid - - 0.1 0.1 5 Cedrol 0.05 0.05 0.05 0.05 6 solubilizer One One One One 7
- Spices appropriate amount appropriate amount appropriate amount appropriate amount 8 Hydrogenated Polydecene 0.3 0.3 0.3 0.3 9
- Carbomer 0.15 0.15 0.15 0.15 0.15 10 corrector appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount 11 antiseptic appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount
- Example 11 the raw materials 3 and 4 were dispersed in the raw material 2 at the composition ratio (unit weight %) shown in Table 7 below, and then the raw material 5 was added and dissolved. After confirming the dissolution, the raw materials 6-8 were dissolved and stirred uniformly.
- Raw materials 9-11 were sequentially added to Raw Material 1 and uniformly stirred, and the ethanol phase was gradually added to the aqueous phase and stirred uniformly for 10 minutes to prepare a cosmetic solution.
- Examples 12-14 were prepared in the same manner as in Example 11.
- Example 11 Example 12
- Example 13 Example 14
- Beta-sitosterol - 0.2 - 0.2 4 Linoleic acid - - 0.2 0.2 5 Ferulic acid 0.1 0.1 0.1 0.1 6
- Spices appropriate amount appropriate amount appropriate amount appropriate amount 8 Hydrogenated Polydecene 0.3 0.3 0.3 0.3 0.3 9
- Carbomer 0.15 0.15 0.15 0.15 0.15 10 corrector appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount 11 antiseptic appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount appropriate amount
- Solubility and compatibility were evaluated for the cosmetic compositions of Examples 7 to 14. The separation and precipitation of phases were visually observed while stored at 25° C. for 4 weeks, at 4° C. for 4 weeks, and at 45° C. for 4 weeks, and are shown in Tables 8 and 9 below.
- Example 7 Example 8
- Example 9 Example 10 room temperature (25°C) X ⁇ ⁇ ⁇ Refrigerated (4°C) ⁇ ⁇ ⁇ ⁇ high temperature (45°C) X ⁇ ⁇ ⁇
- Example 8 As shown in Table 8, in the case of Examples 8 to 10 using beta-sitosterol and linoleic acid, it was confirmed that Cedrol was dissolved in water. In the case of Example 7 in which beta-sitosterol and linoleic acid were not used, it was confirmed that the powder was dispersed as it was and did not dissolve.
- Example 11 Example 12
- Example 13 Example 14 room temperature (25°C) X ⁇ ⁇ ⁇ Refrigerated (4°C) X ⁇ ⁇ ⁇ high temperature (45°C) X ⁇ ⁇ ⁇
- Example 14 As shown in Table 9, in Examples 12 to 14 using beta-sitosterol and linoleic acid, it was confirmed that ferulic acid was dissolved in water. In Example 14, in which beta-sitosterol and linoleic acid were simultaneously used, it was confirmed that a stable formulation was maintained without precipitation even under refrigerated conditions. In the case of Example 11 in which beta-sitosterol and linoleic acid were not used, it was confirmed that the powder was dispersed as it was and did not dissolve.
- beta-sitosterol and linoleic acid of the present invention affect the solubility of Cedrol and ferulic acid so that they can be stably dispersed in the cosmetic. confirmed to help.
- Cedrol and Ferulic acid of the present invention can be stably dispersed in cosmetics when beta-sitosterol and Linoleic acid are treated together.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
샘플번호 | 조성물 |
비교예 1 | 세드롤(Cedrol) |
비교예 2 | 페룰산(Ferulic acid) |
비교예 3 | 베타-시토스테롤(Beta-sitosterol) |
비교예 4 | 리놀레산(Linoleic acid) |
실시예 1 | 세드롤(Cedrol) + 베타-시토스테롤(Beta-sitosterol) |
실시예 2 | 세드롤(Cedrol) + 리놀레산(Linoleic acid) |
실시예 3 | 세드롤(Cedrol) + 베타-시토스테롤(Beta-sitosterol) + 리놀레산(Linoleic acid) |
실시예 4 | 페룰산(Ferulic acid) + 베타-시토스테롤(Beta-sitosterol) |
실시예 5 | 페룰산(Ferulic acid) + 리놀레산(Linoleic acid) |
실시예 6 | 페룰산(Ferulic acid) + 베타-시토스테롤(Beta-sitosterol) + 리놀레산(Linoleic acid) |
시료 | 비교예 1 | 비교예 2 | 비교예 3 | 비교예 4 | 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 | 실시예 5 | 실시예 6 |
Trolox μmol equivalents/mL |
0.104 | 0.981 | 0.051 | 0.023 | 0.163 |
0.148 | 0.213 |
1.051 |
0.998 |
1.026 |
시료 | 양성대조군 | 비교예 1 | 비교예 2 | 비교예 3 | 비교예 4 | 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 | 실시예 5 | 실시예 6 |
멜라닌 생성 저해율(%) |
19.8% | 17.5% | 16.3% | 1.7% | 6.7% | 18.1% |
19.0% |
20.1% |
15.4% |
19.9% |
18.5% |
시료 | 양성대조군 | 비교예 1 | 비교예 2 | 비교예 3 | 비교예 4 | 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 | 실시예 5 | 실시예 6 |
콜라겐 생성율(%) |
32.1% | 27.9% | 8.8% | 2.4% | -2.5% | 27.6% |
21.2% |
23.5% |
6.6% |
7.6% |
4.1% |
시료 | 양성대조군 | 비교예 1 | 비교예 2 | 비교예 3 | 비교예 4 | 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 | 실시예 5 | 실시예 6 |
히알루론산 생성율(%) |
45.9% | 5.6% | 32.2% | -3.0% | 4.1% | 3.9% | 4.4% |
2.8% |
36.3% |
42.2% |
42.9% |
원료 | 성분명 | 실시예 7 | 실시예 8 | 실시예 9 | 실시예 10 |
1 | 정제수 | To 100 | To 100 | To 100 | To 100 |
2 | 에탄올 | 2 | 2 | 2 | 2 |
3 | 베타-시토스테롤(Beta-sitosterol) | - | 0.1 | - | 0.1 |
4 | 리놀레산(Linoleic acid) | - | - | 0.1 | 0.1 |
5 | 세드롤(Cedrol) | 0.05 | 0.05 | 0.05 | 0.05 |
6 | 가용화제 | 1 | 1 | 1 | 1 |
7 | 향료 | 적량 | 적량 | 적량 | 적량 |
8 | 하이드로제네이티드폴리데센 | 0.3 | 0.3 | 0.3 | 0.3 |
9 | 카보머 | 0.15 | 0.15 | 0.15 | 0.15 |
10 | 중화제 | 적량 | 적량 | 적량 | 적량 |
11 | 방부제 | 적량 | 적량 | 적량 | 적량 |
성분명 | 실시예 11 | 실시예 12 | 실시예 13 | 실시예 14 | |
1 | 정제수 | To 100 | To 100 | To 100 | To 100 |
2 | 에탄올 | 2 | 2 | 2 | 2 |
3 | 베타-시토스테롤(Beta-sitosterol) | - | 0.2 | - | 0.2 |
4 | 리놀레산(Linoleic acid) | - | - | 0.2 | 0.2 |
5 | 페룰산(Ferulic acid) | 0.1 | 0.1 | 0.1 | 0.1 |
6 | 가용화제 | 1 | 1 | 1 | 1 |
7 | 향료 | 적량 | 적량 | 적량 | 적량 |
8 | 하이드로제네이티드폴리데센 | 0.3 | 0.3 | 0.3 | 0.3 |
9 | 카보머 | 0.15 | 0.15 | 0.15 | 0.15 |
10 | 중화제 | 적량 | 적량 | 적량 | 적량 |
11 | 방부제 | 적량 | 적량 | 적량 | 적량 |
실시예 7 | 실시예 8 | 실시예 9 | 실시예 10 | |
실온 (25℃) | X | △ | ○ | ○ |
냉장 (4℃) | △ | ○ | ○ | ○ |
고온 (45℃) | X | ○ | ○ | ○ |
실시예 11 | 실시예 12 | 실시예 13 | 실시예 14 | |
실온 (25℃) | X | ○ | ○ | ○ |
냉장 (4℃) | X | △ | △ | ○ |
고온 (45℃) | X | ○ | ○ | ○ |
Claims (16)
- 세드롤(Cedrol) 또는 페룰산(Ferulic acid); 및베타-시토스테롤(Beta-sitosterol) 및 리놀레산(Linoleic acid)으로 이루어진 군으로부터 선택된 하나 또는 그 이상;을 포함하는, 피부 미백용 화장료 조성물.
- 제 1항에 있어서,상기 화장료는 화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션, 밤(balm), 연고 또는 세정제의 제형인, 피부 미백용 화장료 조성물.
- 제 1항에 있어서,상기 조성물은 멜라닌 감소 효과를 갖는, 피부 미백용 화장료 조성물.
- 세드롤(Cedrol) 또는 페룰산(Ferulic acid); 및베타-시토스테롤(Beta-sitosterol) 및 리놀레산(Linoleic acid)으로 이루어진 군으로부터 선택된 하나 또는 그 이상;을 포함하는, 항산화용 화장료 조성물.
- 제 4항에 있어서,상기 화장료는 화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션, 밤(balm), 연고 또는 세정제의 제형인, 항산화용 화장료 조성물.
- 제 4항에 있어서,상기 조성물은 자유라디칼 소거 효과를 갖는, 항산화용 화장료 조성물.
- 세드롤(Cedrol) 또는 페룰산(Ferulic acid); 및베타-시토스테롤(Beta-sitosterol) 및 리놀레산(Linoleic acid)으로 이루어진 군으로부터 선택된 하나 또는 그 이상;을 포함하는, 피부 탄력 증진 또는 주름 개선용 화장료 조성물.
- 제 7항에 있어서,상기 화장료는 화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션, 밤(balm), 연고 또는 세정제의 제형인, 피부 탄력 증진 또는 주름 개선용 화장료 조성물.
- 제 7항에 있어서,상기 조성물은 콜라겐 합성 촉진 효과를 갖는, 피부 탄력 증진 또는 주름 개선용 화장료 조성물.
- 세드롤(Cedrol) 또는 페룰산(Ferulic acid); 및베타-시토스테롤(Beta-sitosterol) 및 리놀레산(Linoleic acid)으로 이루어진 군으로부터 선택된 하나 또는 그 이상;을 포함하는, 피부 보습용 화장료 조성물.
- 제 10항에 있어서,상기 화장료는 화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션, 밤(balm), 연고 또는 세정제의 제형인, 피부 보습용 화장료 조성물.
- 제 10항에 있어서,상기 조성물은 히알루론산 합성 촉진 효과를 갖는, 피부 보습용 화장료 조성물.
- 세드롤(Cedrol) 또는 페룰산(Ferulic acid); 및베타-시토스테롤(Beta-sitosterol) 및 리놀레산(Linoleic acid)으로 이루어진 군으로부터 선택된 하나 또는 그 이상;을 포함하는, 식품 조성물.
- 제 13항에 있어서,상기 조성물은 피부 미백용; 항산화용; 피부 탄력 증진 또는 주름 개선용; 또는 피부 보습용; 식품 조성물.
- 세드롤(Cedrol) 또는 페룰산(Ferulic acid); 및베타-시토스테롤(Beta-sitosterol) 및 리놀레산(Linoleic acid)으로 이루어진 군으로부터 선택된 하나 또는 그 이상;을 포함하는, 의약외품 조성물.
- 제 15항에 있어서,상기 조성물은 피부 미백용; 항산화용; 피부 탄력 증진 또는 주름 개선용; 또는 피부 보습용; 의약외품 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023538822A JP2024502775A (ja) | 2020-12-23 | 2021-12-22 | 皮膚改善用組成物 |
CN202180022990.7A CN115297828A (zh) | 2020-12-23 | 2021-12-22 | 皮肤改善用组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0182508 | 2020-12-23 | ||
KR20200182508 | 2020-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022139458A1 true WO2022139458A1 (ko) | 2022-06-30 |
Family
ID=82158456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/019608 WO2022139458A1 (ko) | 2020-12-23 | 2021-12-22 | 피부 개선용 조성물 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2024502775A (ko) |
KR (1) | KR20220091410A (ko) |
CN (1) | CN115297828A (ko) |
WO (1) | WO2022139458A1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999000108A1 (en) * | 1997-06-27 | 1999-01-07 | Unilever Plc | Improved cosmetic composition containing ferulic acid esters |
KR20030037992A (ko) * | 2001-11-08 | 2003-05-16 | 주식회사 엘지생활건강 | 시토스테롤을 함유하는 피부미백용 조성물 |
JP2003160476A (ja) * | 2001-09-11 | 2003-06-03 | Kao Corp | 皮膚外用剤 |
JP3723791B2 (ja) * | 2001-09-11 | 2005-12-07 | 花王株式会社 | 化粧料 |
-
2021
- 2021-12-22 KR KR1020210185238A patent/KR20220091410A/ko active IP Right Grant
- 2021-12-22 JP JP2023538822A patent/JP2024502775A/ja active Pending
- 2021-12-22 WO PCT/KR2021/019608 patent/WO2022139458A1/ko active Application Filing
- 2021-12-22 CN CN202180022990.7A patent/CN115297828A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999000108A1 (en) * | 1997-06-27 | 1999-01-07 | Unilever Plc | Improved cosmetic composition containing ferulic acid esters |
JP2003160476A (ja) * | 2001-09-11 | 2003-06-03 | Kao Corp | 皮膚外用剤 |
JP3723791B2 (ja) * | 2001-09-11 | 2005-12-07 | 花王株式会社 | 化粧料 |
KR20030037992A (ko) * | 2001-11-08 | 2003-05-16 | 주식회사 엘지생활건강 | 시토스테롤을 함유하는 피부미백용 조성물 |
Non-Patent Citations (1)
Title |
---|
RYU JONG SEONG, CHO HWAN IL, WON JI HEE, JEON MI NA, KWON OH SUN, WON BO MI, LIM JUN MAN, LEE SANG HWA: "Anti-aging Effects of Cedrol and Collagen-derived Peptide", JOURNAL OF THE SOCIETY OF COSMETIC SCIENTISTS OF KOREA, SOCIETY OF COSMETIC SCIENTISTS OF KOREA, KOREA, vol. 41, no. 3, 30 September 2015 (2015-09-30), Korea , pages 229 - 235, XP055946598, ISSN: 1226-2587, DOI: 10.15230/SCSK.2015.41.3.229 * |
Also Published As
Publication number | Publication date |
---|---|
KR20220091410A (ko) | 2022-06-30 |
JP2024502775A (ja) | 2024-01-23 |
CN115297828A (zh) | 2022-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020060060A1 (ko) | 병풀 부정근 추출물을 유효성분으로 함유하는 피부 미백 및 주름개선용 화장료 조성물 | |
KR20130083796A (ko) | 피부주름 개선 및 미백용 조성물 | |
CN111315353B (zh) | 包含粗齿绣球提取物的因紫外线引起的人皮肤细胞损伤改善用组合物 | |
KR20170025375A (ko) | 피부 개선용 조성물 | |
KR101948828B1 (ko) | 기능성 펩타이드, 성장인자 및 귤속 과피 발효물을 포함하는 피부 재생, 주름 개선 또는 항산화용 조성물 | |
KR20140013795A (ko) | 진세노사이드 f2를 유효 성분으로 포함하는 주름개선, 피부미백 또는 여드름 개선용 화장료 조성물 | |
WO2016010283A1 (ko) | 납떼기콩 오일을 포함하는 조성물 | |
KR102343112B1 (ko) | 기능성 펩타이드, 아미노산, 캘러스 추출물 및 발효물을 포함하는 항노화 조성물 | |
WO2022139458A1 (ko) | 피부 개선용 조성물 | |
WO2020111540A1 (ko) | 안토시아닌-폴리사카라이드 복합체를 유효성분으로 포함하는, 노화 또는 노화 관련 질환 예방 또는 치료용 약학적 조성물 | |
KR20170025355A (ko) | 피부 개선용 조성물 | |
KR20170025363A (ko) | 피부 개선용 조성물 | |
KR101720712B1 (ko) | 레비스틸라이드 a을 포함하는 피부 개선용 조성물 | |
KR101672841B1 (ko) | 피부 개선용 조성물 | |
KR20150049417A (ko) | 하르파고사이드를 포함하는 피부 재생, 주름 개선, 항산화, 항염증 및 피부 미백용 조성물 | |
KR20150019562A (ko) | 피부 재생, 주름개선, 항산화, 항염증 및 피부 미백용 조성물 | |
KR20150019546A (ko) | 피부 재생, 주름개선, 항염증 및 피부 미백용 조성물 | |
KR20150019566A (ko) | 피부 재생, 주름개선, 항산화, 항염증 및 피부 미백용 조성물 | |
WO2024128333A1 (ko) | 푸른여로 추출물을 이용한 피부 주름 개선 및 피부 미백용 조성물 | |
WO2022050819A1 (ko) | 효소처리 크릴 오일 추출물을 유효성분으로 포함하는 항염증, 피부 주름개선, 보습 및 피부 재생 촉진용 조성물 | |
KR102000520B1 (ko) | 피부 재생, 주름개선, 항산화, 항염증 및 피부 미백용 조성물 | |
WO2020067663A1 (ko) | 피부 턴오버 촉진 및 멜라닌 배출 촉진용 조성물 | |
KR101711513B1 (ko) | 피부 개선용 조성물 | |
KR20150057763A (ko) | 한방향 유효성분 트리데칸(Tridecane)을 피부 유용성분으로 함유하는 화장료 조성물 | |
KR20150057759A (ko) | 한방향 유효성분 리모넨(Limonene)을 피부 유용성분으로 함유하는 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21911525 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18269226 Country of ref document: US Ref document number: 2023538822 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 20/10/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21911525 Country of ref document: EP Kind code of ref document: A1 |